Cardio-cerebrovascular diseases (CVDs), one of the leading causes of death worldwide, are a broad spectrum of serious health conditions including heart disease, hypertension, stroke, atherosclerosis, retinopathy, etc. The pathogenesis and clinical features of CVDs have been well-studied in the past decades. However, therapies that specifically target disease-causing molecules or cells without affecting normal tissue thus enabling precision treatment are limited. The rapid advances in bio-nanotechnology and bioactive substances enable the feasibility of design and implementation of strategies for targeted drug delivery to treat CVDs and cardio-cerebrovascular regenerative medicine.
In this Research Topic, we would like to create a forum for current advances on preclinical and clinical studies utilizing bioactive substances materials, including bio-ceramics, bio-glasses, polymers, hydrogels, decellularized organs/tissues, organ- and/or tissue-derived stem cells, exosomes, proteins, micro-RNAs, lncRNAs, active components of traditional Chinese medicine and related composites, to design and develop therapies that specifically target CVD-causing molecules or cells to support, enhance, or replace damaged CVD tissues or biological functions. We welcome preclinical and clinical studies focusing on testing the efficacies of bioactive substances-mediated target therapeutic strategies against the development of CVDs and defining the underlying mechanisms. In addition, for manuscripts dealing with plant extracts or other natural substances/compounds, the composition and the stability of the study material must be described in sufficient detail. In particular, for extracts, chromatograms with the characterization of the dominating compound(s) are requested. The level of purity must be proven and included.
Topics of interest include but are not limited to:
• Design, development, and therapeutic effect test of bioactive substances-mediated targeted strategies against the development of CVDs, including heart disease, hypertension, stroke, atherosclerosis, oncocardiology, etc., in small and large animal models.
• Design, development, and clinical therapeutic efficacy test of bioactive substances-mediated targeted strategies against the development of CVDs, including heart disease, hypertension, stroke, atherosclerosis, oncocardiology, etc., in human patients.
• The molecular mechanisms of bioactive substances-mediated therapeutic strategies that target cardiovascular glucose and lipid metabolism, oxidative stress, inflammation, cell regenerative, angiogenesis, and/or tissue remodeling.
• Inspection and detection technology of markers related to CVDs.
Cardio-cerebrovascular diseases (CVDs), one of the leading causes of death worldwide, are a broad spectrum of serious health conditions including heart disease, hypertension, stroke, atherosclerosis, retinopathy, etc. The pathogenesis and clinical features of CVDs have been well-studied in the past decades. However, therapies that specifically target disease-causing molecules or cells without affecting normal tissue thus enabling precision treatment are limited. The rapid advances in bio-nanotechnology and bioactive substances enable the feasibility of design and implementation of strategies for targeted drug delivery to treat CVDs and cardio-cerebrovascular regenerative medicine.
In this Research Topic, we would like to create a forum for current advances on preclinical and clinical studies utilizing bioactive substances materials, including bio-ceramics, bio-glasses, polymers, hydrogels, decellularized organs/tissues, organ- and/or tissue-derived stem cells, exosomes, proteins, micro-RNAs, lncRNAs, active components of traditional Chinese medicine and related composites, to design and develop therapies that specifically target CVD-causing molecules or cells to support, enhance, or replace damaged CVD tissues or biological functions. We welcome preclinical and clinical studies focusing on testing the efficacies of bioactive substances-mediated target therapeutic strategies against the development of CVDs and defining the underlying mechanisms. In addition, for manuscripts dealing with plant extracts or other natural substances/compounds, the composition and the stability of the study material must be described in sufficient detail. In particular, for extracts, chromatograms with the characterization of the dominating compound(s) are requested. The level of purity must be proven and included.
Topics of interest include but are not limited to:
• Design, development, and therapeutic effect test of bioactive substances-mediated targeted strategies against the development of CVDs, including heart disease, hypertension, stroke, atherosclerosis, oncocardiology, etc., in small and large animal models.
• Design, development, and clinical therapeutic efficacy test of bioactive substances-mediated targeted strategies against the development of CVDs, including heart disease, hypertension, stroke, atherosclerosis, oncocardiology, etc., in human patients.
• The molecular mechanisms of bioactive substances-mediated therapeutic strategies that target cardiovascular glucose and lipid metabolism, oxidative stress, inflammation, cell regenerative, angiogenesis, and/or tissue remodeling.
• Inspection and detection technology of markers related to CVDs.